{"entity":{"id":"taris-biomedical","kind":"company","name":"TARIS Biomedical","aka":["TARIS Biomedical LLC","TARIS Bio"],"tldr":"TARIS Biomedical made a small silicone device that sits in the bladder and slowly releases medicine there, aimed at bladder cancer. Johnson & Johnson bought it in 2019, and its first product, TAR-200, was developed further by J&J.","summary":"TARIS Biomedical was a privately owned company developing drug delivery technology for bladder diseases including cancer. Its lead clinical-stage product, TAR-200, used the TARIS System, a silicone-based device that releases medication continuously into the bladder. Johnson & Johnson announced the acquisition on 20 December 2019 without disclosing terms; TARIS was to keep a research presence in Lexington, Massachusetts and join the oncology area of Janssen Research & Development. J&J says the technology arose from research at MIT's Koch Institute for Integrative Cancer Research. Third Rock Ventures describes TARIS as focused on urological disorders.","asOf":"2026-11-04","links":[{"label":"Johnson & Johnson acquires TARIS (press release, 20 December 2019)","url":"https://s203.q4cdn.com/636242992/files/doc_news/2019/12/News-Release-12-20-2019-1690579526717972.pdf"},{"label":"Third Rock Ventures portfolio entry","url":"https://www.thirdrockventures.com/portfolio/taris"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":["devices","targeted-therapy"],"technologies":["bcg-and-intravesical-therapy"],"targets":[],"drugs":["tar-200"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The existing OnCo drug records tar-200 (gemcitabine intravesical system) came from TARIS and can link here; tar-210 is a later J&J programme on the same delivery approach and is not attributed to TARIS by the sources read.","A third-party deal database names Polaris Partners, Flagship Pioneering and RA Capital as sellers; not added because no primary source was read.","The old website (tarisbiomedical.com) now redirects to Johnson & Johnson.","Founding year not stated (2011 is Third Rock's year of investment)."],"hq":"Lexington, MA","country":"US","companyType":"devices","stage":"acquired","investors":["third-rock-ventures"],"funding":[],"acquiredBy":"johnson-johnson"},"route":"/companies/taris-biomedical/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"section":[{"id":"devices","kind":"section","name":"Devices & Physical Therapies","route":"/fronts/devices/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"bcg-and-intravesical-therapy","kind":"technology","name":"Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)","route":"/technologies/bcg-and-intravesical-therapy/"}],"drug":[{"id":"tar-200","kind":"drug","name":"Gemcitabine intravesical system (TAR-200)","route":"/drugs/tar-200/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"},{"id":"third-rock-ventures","kind":"company","name":"Third Rock Ventures","route":"/companies/third-rock-ventures/"}]}}